A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.
This is a Phase III, randomized, double-blind, placebo-controlled, multicenter, global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1(tegafur/ gimeracil/ oteracil) or gemcitabine/cisplatin) as adjuvant treatment in participants with BTC after resection with curative intent. This study will be conducted in patients with BTC who are at risk of recurrence after resection with curative intent.
Inclusion Criteria:
Exclusion Criteria:
Esslingen A. N., 73730, Germany
Tricase, Lecce, 73039, Italy
Kitaadachi-gun, 362-0806, Japan
Mitaka-shi, 181-8611, Japan
Suita-shi, 565-0871, Japan
Muang, 34000, Thailand
Muang, 50200, Thailand
Naimuang, 30000, Thailand
Fatih-Istanbul, 34098, Turkey (Türkiye)
Glasgow, Scotland, G12 0YN, United Kingdom